{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:04:52Z","timestamp":1760238292001,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Despite offering an attractive option, the role of allogeneic stem cell transplantation (alloSCT) for treatment of multiple myeloma (MM) remains unclear. Methods: Recognizing the paucity of data in the Asian population, we retrospectively evaluated the outcomes of 24 patients (median age 52) undergoing alloSCT between April 2003 and November 2017. Results: The median time from diagnosis to alloSCT was 39.4 months. The majority of the patients (70.8%) underwent alloSCT followed by reduced intensity conditioning regimens after a median of five lines of therapy. Among 24 patients, 15 patients (62.5%) had a high-risk MM feature. The two-year relapse-free survival (RFS) and overall survival (OS) of the total patients were 29.2 \u00b1 9.3% and 44.3 \u00b1 10.3%, respectively. Patients who were treated with less chemotherapy lines (&lt;5) before alloSCT had a prolonged RFS and OS. All patients (seven patients) who received a myeloablative conditioning regimen had high-risk features, but two out of seven patients showed long-term survival without lasting sequelae. Nine patients (37.5%) experienced non-relapse mortality (NRM) within one year after alloSCT (the one-year cumulative incidence of NRM was 38.3 \u00b1 10.1%). Conclusion: AlloSCT can still be implemented as effective salvage option in the treatment of relapsed\/refractory high-risk MM. The optimal timing of alloSCT remains to be determined.<\/jats:p>","DOI":"10.3390\/jcm9082354","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:26:01Z","timestamp":1595503561000},"page":"2354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic Stem Cell Transplantation in Relapsed\/Refractory Multiple Myeloma Treatment: Is It Still Relevant?"],"prefix":"10.3390","volume":"9","author":[{"given":"Hyunkyung","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":false,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"},{"name":"Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-018-0071-x","article-title":"Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study","volume":"8","author":"Suzuki","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2019.217448","article-title":"Daratumumab-Based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies","volume":"105","author":"Mateos","year":"2020","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14728214.2016.1186644","article-title":"Emerging antibodies for the treatment of multiple myeloma","volume":"21","author":"Zagouri","year":"2016","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-Versus-Myeloma effect: Proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbmt.2013.01.003","article-title":"Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: The cost of freedom","volume":"19","author":"Kim","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT chronic malignancies working party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: A systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: A population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: Health of the health care system in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc. Work Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","article-title":"How I treat high-risk myeloma","volume":"126","author":"Lonial","year":"2015","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbmt.2015.07.021","article-title":"Reducing treatment-related mortality did not improve outcomes of allogeneic myeloablative hematopoietic cell transplantation for high-risk multiple myeloma: A university of michigan prospective series","volume":"22","author":"Pawarode","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.23412","article-title":"Long-Term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma","volume":"88","author":"Crocchiolo","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimar\u00e3es, J.E., and Vasconcelos, M.H. (2020). Multiple myeloma: Available therapies and causes of drug resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Da Vi\u00e0, M.C., Cicco, S., Leone, P., Di Lernia, G., Giannico, D., Desantis, V., Frassanito, M.A., Morizio, A., and Delgado Tascon, J. (2019). High-Risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J. Clin. Med., 8.","DOI":"10.20944\/preprints201906.0145.v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","article-title":"Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and\/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death","volume":"32","author":"Moreau","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bmt.1705161","article-title":"Long-Term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma","volume":"36","author":"Gerull","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2016.03.001","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: Impact of disease risk and post allograft minimal residual disease on survival","volume":"16","author":"Dhakal","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12758","article-title":"Outcome of allogeneic transplantation in newly diagnosed and relapsed\/refractory multiple myeloma: Long-Term follow-up in a single institution","volume":"97","author":"Franssen","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-Term follow-up","volume":"29","author":"Iacobelli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bbmt.2019.03.016","article-title":"A Phase I\/II, Open-Label, Prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study","volume":"25","author":"Park","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.beha.2007.09.007","article-title":"Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?","volume":"20","author":"Bensinger","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983\u201393 and 1994\u20138 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjh.12123","article-title":"Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: A long-term follow-up study","volume":"160","author":"Sahebi","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/8\/2354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:07Z","timestamp":1760176267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/8\/2354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["jcm9082354"],"URL":"https:\/\/doi.org\/10.3390\/jcm9082354","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,7,23]]}}}